And this comes after a committee reviewed the Phase 3 trial of Novocure's lung cancer treatment candidate.
The independent data monitoring committee said the interim results of the trial of Novocure's tumor-treating fields should be accelerated. The TTFs are electric fields designed to disrupt cell division in stage 4 non-small-cell lung cancer.
The panel's recommendations "support the potential for TTFields to make a significant difference in treatment outcomes for patients with non-small-cell lung cancer, whether used together with immune checkpoint inhibitors or docetaxel,” Novocure executive chairman William Doyle said in a statement.
And Regeneron's COVID-19 cocktail shows promise as a preventative treatment.
The company's Phase 3 trial gave the drug to "recently infected" people who were asymptomatic.
"Regen-COV reduced the overall risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day," Regeneron said in a statement.
Regeneron said it will ask the U.S. Food and Drug Administration to expand the drug's authorization among people exposed to the virus who haven't yet been vaccinated.
Watch TheStreet Live: Everything Jim Cramer Is Watching Tuesday.